Persons with depression are differentially affected by metabolic alterations, notably, insulin resistance and dyslipidemia. Metabolic alterations affect acute pharmacotherapy response and predispose risk for cardiovascular diseases. We aimed to extend knowledge pertaining to the depression-metabolic alteration association by evaluating whether depressive symptom severity moderates the association. We conducted a systematic search of PubMed, Ovid and Scopus from inception to May 2025. Two reviewers (S.W. and G.H.L.) independently screened the identified studies. Studies were included if they enrolled adults with depression and reported on at least one metabolic parameter (i.e., fasting glucose, insulin, lipid panels). Standardized mean differences of metabolic parameters were pooled across studies. We identified 28 studies for inclusion. Persons with depression exhibited higher fasting glucose (SMD = 0.30, 95 % CI [0.12, 0.48]) and dyslipidemia [i.e., trends of increased low-density lipoprotein (SMD = 0.21, 95 % CI [-0.03, 0.44]) and lower high-density lipoprotein (SMD = -0.72, 95 % CI [-1.41, -0.03])]. Measures of insulin resistance were positively associated with anhedonia severity, sleep disturbances, and suicidal ideation. Between-study methodological differences, including study design and sociodemographics, affects the synthesis of overall trends. Herein, we identify an association between depressive symptom severity and dysglycemia, dyslipidemia and insulin resistance. The results augment the conceptual framework implicating metabolic disturbances in depression pathophysiology and indirectly support testing that therapeutics currently in development in the treatment of depression (e.g., GLP-1 receptor agonists) may exhibit differential efficacy as a function of illness severity.
Lithium is a first-line treatment for bipolar disorder, especially BD-I. In addition to efficacy in treating acute mania and recurrence prevention in bipolar disorder, lithium's anti-suicide effects have been documented in studies showing reduced rates of completed suicide and serious attempts. To update current knowledge on the topic, we conducted a systematic review and meta-analysis of lithium's impact in randomized controlled trials on suicidality (i.e., suicidal ideation, attempts, and suicide). Herein we followed Cochrane protocols and PRISMA guidelines to search OVID databases (Embase, MedLine, PsychINFO) from January 2013 to July 2024 for randomized trials evaluating lithium's effect on suicidality, specifically reporting suicidal ideation, attempts, or related mortality outcomes. We identified earlier studies from manual reference searching. Two reviewers independently extracted data and assessed quality. From 1793 articles, 15 studies (eight placebo-controlled, n = 1698; seven open-label, n = 1338) met eligibility criteria. Lithium was associated with nonsignificant reductions in suicide attempts (OR = 0.73; 95 % CI = [0.41, 1.31]; 25 in the lithium cohort vs. 63 on placebo) and completed suicide (OR = 0.61; 95 % CI = [0.25, 1.48]; lithium 4 vs. 13 placebo). Heterogeneity in methods and measures used to quantify suicidal ideation prevented quantitative analysis. Methodological limitations affect assay sensitivity for suicidality measures, notably small sample sizes, diagnostic heterogeneity, inadequate treatment fidelity, subtherapeutic lithium levels, and intersubject differences in prior suicidality. Failure to reach statistical significance likely results from type II error, yet lithium's beneficial effects on suicide attempts and completed suicide align with observational studies.
18 September 2024 in Journal of Affective Disorders